Evidence map›Paper›PMID 37931386›Full record

ArticleDiagnostic microbiology and infectious disease2024

Molecular detection of pre-ribosomal RNAs of Mycobacterium bovis bacille Calmette-Guérin and Mycobacterium tuberculosis to enhance pre-clinical tuberculosis drug and vaccine development.

Ming Chang, Sambasivan Venkatasubramanian, Holly Barrett, Kevin B Urdahl, Kris M Weigel, Gerard A Cangelosi, Javeed A Shah, Aparajita Saha, Libing Feng, Kristin N Adams and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic microbiology and infectious disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Ming ChangDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA.
Sambasivan VenkatasubramanianDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
Holly BarrettSeattle Children's Research Institute, Seattle, WA, USA.
Kevin B UrdahlSeattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Department of Immunology, University of Washington, Seattle, WA, USA.
Kris M WeigelDepartment of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, USA.
Gerard A CangelosiDepartment of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, USA.
Javeed A ShahDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA, USA; Veterans' Affairs Puget Sound Healthcare System, Seattle, WA, USA.
Aparajita SahaDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
Libing FengDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
Kristin N AdamsDepartment of Microbiology, University of Washington, Seattle, WA, USA.
David R ShermanDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Nahum SmithDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Chetan SeshadriDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Sean C MurphyDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Microbiology, University of Washington, Seattle, WA, USA. Electronic address: murphysc@uw.edu.
University of Washington · USInfectious Disease Research Institute · US

Funding

Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosisR01AI146194 · NIAID · UNIVERSITY OF WASHINGTON · PI ALLAND, DAVID, SHERMAN, DAVID R · 2020 to 2024
$4.1M
TOLLIP Deficiency, Immune Dysregulation, and Tuberculosis SusceptibilityR01AI136921 · NIAID · UNIVERSITY OF WASHINGTON · PI SHAH, JAVEED ALI · 2018 to 2022
$2.5M
The impact of mucociliary clearance on Mycobacterium tuberculosis pathogenesisR21AI165961 · NIAID · UNIVERSITY OF WASHINGTON · PI SHAH, JAVEED ALI · 2023 to 2024
$457k
Molecular confirmation of tuberculosis treatmentR21AI141944 · NIAID · UNIVERSITY OF WASHINGTON · PI CANGELOSI, GERARD A · 2019 to 2020
$380k
NIAID NIH HHS R01 AI136921NIAID NIH HHS R01 AI146194NIAID NIH HHS R21 AI141944NIAID NIH HHS R21 AI165961
6 · The paper itself

Abstract

Efforts are underway globally to develop effective vaccines and drugs against M. tuberculosis (Mtb) to reduce the morbidity and mortality of tuberculosis. Improving detection of slow-growing mycobacteria could simplify and accelerate efficacy studies of vaccines and drugs in animal models and human clinical trials. Here, a real-time reverse transcription PCR (RT-PCR) assay was developed to detect pre-ribosomal RNA (pre-rRNA) of Mycobacterium bovis bacille Calmette-Guérin (BCG) and Mtb. This pre-rRNA biomarker is indicative of bacterial viability. In two different mouse models, the presence of pre-rRNA from BCG and Mtb in ex vivo tissues showed excellent agreement with slower culture-based colony-forming unit assays. The addition of a brief nutritional stimulation prior to molecular viability testing further differentiated viable but dormant mycobacteria from dead mycobacteria. This research has set the stage to evaluate pre-rRNA as a BCG and/or Mtb infection biomarker in future drug and vaccine clinical studies.

Indexed as

Mycobacterium bovisMycobacterium tuberculosisTuberculosisAnimalsBCG VaccineBiomarkersHumansMiceRNA PrecursorsVaccine DevelopmentBCG VaccineBiomarkersRNA Precursorsmolecular viability testingMycobacterium bovis Bacille Calmette-GuérinMycobacterium tuberculosispre-ribosomal RNA

Identifiers

PMID37931386
PMCPMC10729053
OpenAlexW4387676067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.